

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-10 (cancelled)

Claim 11 (original) A method for blocking or suppressing the inhibitory effect of IL-1 comprising administering an effective amount of a BMP.

Claim 12 (currently amended) The method of ~~[claim 12]~~ claim 11 wherein said BMP is selected from the group consisting of BMP-2 and BMP-9.

Claims 13-20 (cancelled)

Claim 21 (currently amended) A method for inducing chondrogenesis ~~[in a patient in need of same]~~, said method comprising administering ~~[to said patient]~~ an effective amount of a composition comprising non-tissue culture expanded cells isolated from bone marrow.

Claim 22 (original) The method of claim 21 wherein said cells are CD105+ cells.

Claim 23 (original) The method of claim 22 further comprising administering a bone and or cartilage inducing factor.

Claim 24 (original) The method of claim 23 wherein said factor is a BMP.

Claim 25 (original) The method of claim 24 wherein said BMP is selected from the group consisting of BMP-2 and BMP-9.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Cont
B1

Claim 26 (currently amended) A method for treating arthritis, ~~[or other cartilaginous tissue defect in a patient in need of same,]~~ said method comprising administering ~~[to said patient]~~ an effective amount of ~~[the]~~ a composition [of claim 15] comprising non-tissue culture expanded cells isolated from bone marrow.

Claim 27 (currently amended) A method for treating articular cartilage defects or damage ~~[in a patient in need of same,]~~ said method comprising administering ~~[to said patient]~~ an effective amount of ~~[the]~~ a composition [of claim 15] comprising non-tissue culture expanded cells isolated from bone marrow.

Claim 28 (currently amended) A ~~[composition]~~ method for repairing tissue ~~[repair]~~ said ~~[composition]~~ method comprising administering an effective amount of a composition comprising

- 1) non-tissue culture expanded cells isolated from bone marrow and
- 2) a factor selected from a bone [and/or cartilage] inducing factors and cartilage inducing factors.

Claim 29 (currently amended) The ~~[composition]~~ method of claim 28 wherein said isolated cells are CD105+ cells and said factor is a BMP.

Claim 30 (currently amended) The ~~[composition]~~ method of claim 29 further comprising a suitable matrix.

Claim 31 (currently amended) The ~~[composition]~~ method of claim 30 wherein said BMP is selected from the group consisting of BMP-2 and BMP-9.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com